LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter




The Lyme Disease Network receives a commission from Amazon.com for each purchase originating from this site.

When purchasing from Amazon.com, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet 2020 fund drive


The Lyme Disease Network is a non-profit organization funded by individual donations.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » General Support » rheumatoid Arthritis Drug nets $284m for MGH

 - UBBFriend: Email this page to someone!    
Author Topic: rheumatoid Arthritis Drug nets $284m for MGH
Neil M Martin
LymeNet Contributor
Member # 2357

Icon 1 posted      Profile for Neil M Martin     Send New Private Message       Edit/Delete Post   Reply With Quote 
http://www.boston.com/business/healthcare/articles/2007/04/19/drugs (&c)

The Boston Globe
Drug nets $284m for MGH
Foreign royalty sale is second Enbrel windfall
By Christopher Rowland, Globe Staff | April 19, 2007

Massachusetts General Hospital yesterday sold its rights to royalties on foreign sales of the rheumatoid arthritis drug Enbrel for $284 million, a move that eliminates its exposure to market risk and will help it build a research endowment.

The sale to Drug Royalty Corp. Inc., a Toronto investment company, follows the settlement of a patent dispute last year between Mass. General and Enbrel's maker, Amgen Inc., which yielded $248 million for the hospital. In that settlement, Mass. General relinquished rights to royalties on Enbrel sales in the United States.

Mass. General chief executive Dr. Peter Slavin said yesterday that the combined $532 million, plus previous royalties from Enbrel sales, make the drug the biggest generator of licensing revenue in the hospital's history.

"Lightning occasionally strikes in this area," Slavin said.

The deals have also made a rich man of biologist Brian Seed, the Mass. General researcher whose discoveries were crucial to Enbrel's development.

Seed discovered a way to fuse proteins that act as decoys. Enbrel researchers used that technique for arthritis, blocking the body's inflammatory response to arthritic joint tissue.

Seed received $62 million from last year's settlement and $71 million from yesterday's sale. Those payouts represent 25 percent of the two deals' total, a standard share for inventors under the hospital's licensing arrangements.

Worldwide sales of Enbrel in 2006 were $4.4 billion, including $2.9 million in the United States. Mass. General and Seed could have expected to receive tens of millions of dollars a year in ongoing royalties, but the hospital decided to sell its remaining rights to protect it from market changes that could potentially cut into Enbrel sales, Slavin said.

Enbrel, which has also been approved by the Food and Drug Administration to treat psoriasis, faces competition from Abbott Laboratories' Humira and Centocor Inc.'s Remicade.

"We certainly believe in the product, but there are market forces that you need to consider," said Frances Toneguzzo , director of technology licensing at Mass. General.

"There's an issue with biologics," Toneguzzo continued. "They are very expensive, there are reimbursement issues, it is injected. If there is a small molecule that would do the same thing and you could take it orally, that would be the end of Enbrel."

Building an endowment with proceeds from the sale of royalty rights will help cushion the hospital's research budgets from flat or declining National Institutes of Health funding, Toneguzzo said.

After Seed's share as inventor is subtracted, the hospital's net is $186 million from the Amgen settlement and $213 million from the sale of foreign royalty rights.

Slavin said the $213 million will be divided evenly between Seed's department, molecular biology; the hospital's center for computational biology; and its central coffers.

Christopher Rowland can be reached at [email protected]


Copyright 2007 The New York Times Company

--------------------
Neil

Posts: 697 | From Tucson, AZ USA | Registered: Apr 2002  |  IP: Logged | Report this post to a Moderator
Lymetoo
Moderator
Member # 743

Icon 1 posted      Profile for Lymetoo     Send New Private Message       Edit/Delete Post   Reply With Quote 
That stuff is SOOO dangerous.

--------------------
--Lymetutu--
Opinions, not medical advice!

Posts: 96024 | From Texas | Registered: Feb 2001  |  IP: Logged | Report this post to a Moderator
lou
Frequent Contributor (5K+ posts)
Member # 81

Icon 1 posted      Profile for lou     Send New Private Message       Edit/Delete Post   Reply With Quote 
Maybe that is why they sold it.

I am tired of hearing about the flat or declining budget of NIH. Until recently there had been huge increases in the budget to the point that in only a few years it had doubled. Is there no end to the whining for more money from researchers? Are we getting enough benefit out of them for the funding they get from our tax dollars? Not sure we are. If you take lyme disease as an example, the money is too often spent to enforce an erroneous view of the disease.

Wondering how many people who actually have lyme disease have been told they have rh ar and are being sold this drug. It certainly raises questions about having a vested interest in certain diagnoses, to the exclusion of others. As we know, there is a certain rheumatologist at Mass Gen who likes to exclude lyme disease diagnoses whenever possible.

Posts: 8430 | From Not available | Registered: Oct 2000  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | LymeNet home page | Privacy Statement

Powered by UBB.classic™ 6.7.3


The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:

The Lyme Disease Network of New Jersey
907 Pebble Creek Court, Pennington, NJ 08534 USA


| Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Contact Us

© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to Terms and Conditions.